Novanta Inc. (NASDAQ:NOVT – Get Free Report) CFO Robert Buckley sold 9,957 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $116.77, for a total value of $1,162,678.89. Following the transaction, the chief financial officer directly owned 96,616 shares of the company’s stock, valued at $11,281,850.32. This trade represents a 9.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Robert Buckley also recently made the following trade(s):
- On Friday, February 20th, Robert Buckley sold 1,423 shares of Novanta stock. The stock was sold at an average price of $140.88, for a total value of $200,472.24.
- On Wednesday, January 21st, Robert Buckley sold 1,423 shares of Novanta stock. The shares were sold at an average price of $140.14, for a total value of $199,419.22.
Novanta Price Performance
Novanta stock traded down $1.69 during midday trading on Wednesday, reaching $119.33. The company’s stock had a trading volume of 569,434 shares, compared to its average volume of 457,808. The company has a current ratio of 3.69, a quick ratio of 2.80 and a debt-to-equity ratio of 0.16. The stock has a market cap of $4.26 billion, a PE ratio of 81.73 and a beta of 1.61. Novanta Inc. has a 52 week low of $98.27 and a 52 week high of $149.95. The business has a 50-day moving average price of $135.34 and a 200-day moving average price of $121.22.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on NOVT shares. Robert W. Baird set a $150.00 price target on shares of Novanta in a report on Wednesday, February 25th. Zacks Research raised Novanta from a “strong sell” rating to a “hold” rating in a report on Friday, January 16th. Finally, Weiss Ratings upgraded Novanta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 20th. Three analysts have rated the stock with a Hold rating, According to MarketBeat.com, Novanta presently has an average rating of “Hold” and a consensus price target of $150.00.
Get Our Latest Analysis on Novanta
Institutional Investors Weigh In On Novanta
Several hedge funds have recently added to or reduced their stakes in NOVT. AQR Capital Management LLC lifted its holdings in shares of Novanta by 78.9% during the first quarter. AQR Capital Management LLC now owns 4,231 shares of the technology company’s stock worth $537,000 after purchasing an additional 1,866 shares during the period. Goldman Sachs Group Inc. increased its holdings in Novanta by 1.6% in the first quarter. Goldman Sachs Group Inc. now owns 419,037 shares of the technology company’s stock valued at $53,582,000 after purchasing an additional 6,533 shares during the period. Jane Street Group LLC increased its holdings in Novanta by 1,762.5% in the first quarter. Jane Street Group LLC now owns 61,631 shares of the technology company’s stock valued at $7,881,000 after purchasing an additional 58,322 shares during the period. PNC Financial Services Group Inc. raised its position in Novanta by 27.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,747 shares of the technology company’s stock worth $483,000 after purchasing an additional 815 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Novanta by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 919,666 shares of the technology company’s stock worth $118,585,000 after purchasing an additional 12,789 shares during the last quarter. 98.35% of the stock is currently owned by institutional investors and hedge funds.
About Novanta
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
See Also
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
